FRAMINGHAM, MA -- (MARKET WIRE) -- March 19, 2007 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announced today that they have initiated a two-year carcinogenicity study in Sprague Dawley rats for IoGen. This toxicity study is intended to probe the possible effects on rodents of supraphysiological doses of IoGen. In the study, the animals will be given doses up to approximately 100 times the equivalent human dose being taken in the ongoing Phase III pivotal study for IoGen. The protocol for the two-year study has completed a special protocol assessment review by the FDA.
